Plain-English translation of NCT06329869 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called for people with advanced esophageal squamous cell carcinoma—a type of throat cancer that has spread or come back after other treatments. The medication works by targeting a specific protein (called Trop-2) that appears on cancer cells. Researchers believe this treatment may help patients whose cancer has stopped responding to standard chemotherapy and immunotherapy.
Many people with advanced esophageal squamous cell carcinoma run out of effective treatment options after standard chemotherapy and immunotherapy stop working. This trial explores whether the medication, which uses a different approach to attack cancer cells, could offer hope to patients who have limited choices left.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive as an intravenous infusion (through an IV into your vein). You would need to provide tumor tissue samples so researchers can confirm that your cancer has the target protein (Trop-2). Throughout the trial, you would have regular visits for blood tests, scans to monitor your cancer, and check-ins with your doctor to track how you're responding and manage any side effects. The trial is currently recruiting approximately 35 patients.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Taiwan
Phase
Testing effectiveness
Sponsor
National Taiwan University Hospital
Collaborators
Gilead Sciences
Enrollment target
~35 participants
Started
August 2024
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Chih-Hung Hsu, M.D., Ph.D.
National Taiwan University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.